Andrew Technologies has obtained 510 (k) clearance from the US Food and Drug Administration (FDA) for its Autologous Fat Transfer device.
The liposuction device, which is based on Tissue Liquefaction Technology, reinjects the adipose tissue (fat) harvested during a HydraSolve liposuction procedure into the same patient for rejuvenation or augmentation.
Hydrasolve combines natural saline solution with low levels of pressure and temperature and liquefies only targeted fat tissue while preserving blood vessels, nerves and connective tissue integrity.
The specially designed HydraSolve cannula is also manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue, claims the company.
Meridian Plastic Surgeons plastic surgeon Dr Bruce Van Natta said, "I have found that HydraSolve rapidly removes fat and produces a nearly bloodless fat layer of uniform particles that can be easily injected into breasts and other target tissues."
Andrew Technologies CEO Tom Albright said, "We are thrilled to achieve our second FDA clearance in less than 6 months, as a startup medical device company that is quite an accomplishment."
